Drug intelligence / Profile preview

AM6588

Development stage: Preclinical
Lead developer: MAK Scientific
Modality: Small Molecules

Overview

AM6588 is a peripherally restricted, small molecule neutral antagonist of the cannabinoid receptor 1 (CB1) being developed by MAK Scientific Management. It is designed to treat fibrotic diseases, such as liver and kidney fibrosis, by targeting peripheral CB1 receptors while avoiding the central nervous system. This approach aims to provide the therapeutic benefits of CB1 blockade—such as anti-fibrotic and metabolic effects—without the neuropsychiatric side effects associated with earlier, brain-penetrant CB1 inverse agonists like rimonabant.

Other names: AM6588AM-6588AM 6588

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on AM6588.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM6588.

Explore the full profile